AKTX - Akari Therapeutics Plc

1.16
0.045   3.862%

Share volume: 19,020
Last Updated: 04-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$1.12
0.04
0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
24%
Profitability 0%
Dept financing 50%
Liquidity 34%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.52%
1 Month
28.89%
3 Months
-9.38%
6 Months
-62.09%
1 Year
-17.14%
2 Year
-69.54%
Key data
Stock price
$1.16
P/E Ratio 
0.00
DAY RANGE
$1.01 - $1.16
EPS 
$0.00
52 WEEK RANGE
$0.85 - $4.40
52 WEEK CHANGE
-$11.79
MARKET CAP 
705.254 M
YIELD 
N/A
SHARES OUTSTANDING 
12.145 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
0.67
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$12,760
AVERAGE 30 VOLUME 
$27,497
Company detail
CEO: Rachelle Jacques
Region: US
Website: akaritx.com
Employees: 9
IPO year: 2015
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Akari Therapeutics, Plc focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities.

Recent news
loading